Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine

by B2i | Feb 10, 2022 | Press Releases

The exclusive license agreement between Dyadic and Phibro utilizes Dyadic engineered C1-cells to produce specific targeted antigens for development and commercialization of a poultry vaccine for a targeted disease.JUPITER, Fla., Feb. 10, 2022 — Dyadic...

Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference

by B2i | Feb 7, 2022 | Press Releases

JUPITER, Fla., Feb. 07, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform...

Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process

by B2i | Jan 20, 2022 | Press Releases

JUPITER, Fla., Jan. 20, 2022 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...

Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan

by B2i | Dec 22, 2021 | Press Releases

JUPITER, Fla., Dec. 22, 2021 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...

Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform

by B2i | Dec 17, 2021 | Press Releases

JUPITER, Fla., Dec. 17, 2021 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying, and...